Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
3/21/23 Altimmune (ALT) Pemvidutide for Obesity Subscribers Only Subscribers Only Subscribers Only
3/21/23 Altimmune (ALT) Pemvidutide for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
3/20/23 Biogen (BIIB) Tofersen for Amyotrophic Lateral Sclerosis (ALS) Subscribers Only Subscribers Only Subscribers Only
3/16/23 Astellas Pharma (4503:JP) Xtandi for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
3/16/23 Pfizer (PFE) Paxlovid for COVID-19 Treatment Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
03/22/23 Subscribers Only Subscribers Only Trial Data - Updated Results
03/22/23 Subscribers Only Subscribers Only Company - Analyst/R&D Update
03/22/23 Subscribers Only Subscribers Only Trial Data - Updated Results
03/23/23 Subscribers Only Subscribers Only Trial Announcement - Initiation
03/23/23 Subscribers Only Subscribers Only Regulatory - Meeting with FDA
Back to the top Back to the top